TH77200B - Optimized expression of HPV 52 L1 in yeast. - Google Patents

Abstract

DC60 (22/03/48) A synthetic DNA molecule defining protein 52L1 was specifically prepared. This invention provides the proton-coded polyonucleotide HPV 52L1, whereby the polynucleotide. Grand This was optimized for Codon to express high levels in yeast cells in the alternative image of fabrication. The nucleotide sequence of the synthetic molecules was Change to eliminate Yeast Known Termination Signal Synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs) and to produce vaccines and pharmaceutical mixtures consisting of HVP 52 VLPs. The vaccine of this invention provides medical protection. Not effective protection against Infection with papillomavirus throughout Neutralization of antibodies and immune-mediated cells and may have Benefits For the treatment of existing HPV infection, a synthetic DNA molecule defining the 52L1 protein is specifically prepared. This invention provides a polynucleotide that is coded pro-HPV 52L1. Cleotide This was optimized for Codon to express high levels in yeast cells in the alternative image of fabrication. The nucleotide sequence of synthetic gems was Change to eliminate The synthetic molecule termination signal may be used to produce HPV 52 virus-like particles (VLPs) and to produce vaccines and pharmaceutical mixtures containing HPV 52 VLPs. Prepare mountain defenses Not effective protection against Infection with papillomavirus throughout Antibody and cell-mediated immunity and may be useful for the treatment of existing HPV infection.

Claims (8)

Disclaimer (all) which will not appear on the announcement page: Edit 29/7/2016 1. 2. Vector which is composed of nucleic acid molecules of the claim No. 1 3. Host, which Include the vector of claim No. 2 4. Host cell of claim No. 3 where host is cell yeast 5. Host cell of claim No. 4, where yeast cells can be selected. From the group consisting of: Zaccaromises Serivisia, Hancenula Poly Morfa, Pichien Pasthoris, Fear of Veromises Fragilis, Fear of veromycellectis And cisosaccharomizes pombe 6. The host cell of claim 4, where the host cell is Zaccharomysels serivice 7. Methods of production of virus-like particles (VLPs) HPV 52 L1, which consists of (a) the transformation of yeast with nucleic acid molecules of the claim. Article 1 (b) Culture of transformed yeast under conditions that allow the presence of acid molecules. Nucleic to produce recombinant papillovirus protein and (c) separation of recombinant papillovirus protein to produce HPV 52 L1 VLPs. 8. Methods of vaccine preparation. For the treatment or prevention of cervical cancer at In connection with HPV, the method includes the production of HPV 52 L1 VLPs by the Claim Method 7 9. Claim Method 8, where the vaccine continues to include VLPs of at least one category. HPV Addendum 1 0. Clause 9, where at least one additional HPV type is selected from the group that includes: HPV6, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV55, HPV56, HPV58, HPV59, and HPV68 1 1. Vaccine of claim 10, where at least one HPV category contains HPV16 1. 2. Vaccine of claim 11, where the vaccine further contains HPV18 VLPs 1 3. Vaccine Clause 12, where the vaccine consists of HPV6 VLPs and HPV11 VLPs 1 4. Vaccine of claim No. 12 or 12 where the vaccine continues to include HPV31 BLPs 1. 5. Vaccine of claim clause 12. 14 where the vaccine further contains HPV45 VLPs 1 6. Vaccine of claim 15 where the vaccine also contains HPV58 VLPs ------------------- -------------------------------- 1. The nucleic acid molecule consisting of a nucleotide sequence that defines the protein HPV 52 L1, as illustrated in SEO ID NO: 2, the codon optimized nucleic acid sequence for The Show the high level in yeast cells 2. Vector which contains nucleic acid molecules of claim 1 3. Host cell which contains the vector of claim 2 4. Host cell of claim 3. Where host cell is yeast cell 5. host cell of claim 4 where yeast cell is selected from The group consists of: zaccaromy-zeszerevisia, hancenula polymorpha, pisea pastoris. Fear of Veromizes Fragilis, Fear of Veromizes Lactis, and Chizosaccaromises Pombe. 6. Whole cell of claim 4, where the host cell is Zacaromises serivizia 1. 8. Virus-like constituents (VLPs) contain either recombinant L 1 protein or HPV52 recombinant L1 + L2 protein. Where L1 recombinant protein or recombinant L1 + L2 protein is produced in yeast 9.VLPs of claim 8, whereby recombinant L1 protein Or the recombinant protein L1 + L2 is coded by the nucleic acid molecule HPV 52 L1 optimized codeon 1 0.VLPs of claim 9, whereby the acid molecule Optimized nucleic of The codons consist of a sequence of nucleotides. As described in SEQ ID NO: 1 1 1. Methods for the production of VLPs of Clause 9, consisting of (a) the transformation of yeast with an optimized code DNA molecule of the Codon. Identify the protein HPV 52 L 1 or HPV 52 L1 + L2 (b). The cultured yeast was transformed under conditions that emit the optimum expression of the Codon DNA molecule to produce recombinant. Non-papillovirus protein and (c) protein separation of recombitanant palilovirus to produce V LPs of claim No. 9 1. 2. Vaccines containing the VLPs of Clause 9 1. 3. Pharmaceutical Mixture, which contains the VLPs of Clause 9 1. 4. Methods of prevention of HPV infection, including the vaccination of claim 12 to mammals 1. 5. Methods for the induction of immune responses in animals that This includes the provision of the VLPs of claim 11 to mammals 1 6. Virus-like particles of claim 9, where the yeast is selected. A can be from a group that includes Zaccaromice Serivizia, Hancinula Poli Morfa, Pichia Pastoris, Fear of Veromieses Fragilis, Fear of Veromites. Saslactis, and cisosaccharomizes pombe 1 7. The viral-like particle of claim 16, where yeast is Zaccaromaceous Rivizia 1 8. Vaccine of claim 12, which consists of VLPs of at least one additional class HPV 1. 9. Vaccine of claim Article 18. Where at least one additional HPV type can be selected from a group that includes HPV6, HPV11, HPV16, HP V18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV55, HPV56, HPV58, HP V59, and HPV68 2. Clause 19 vaccine, where at least one HPV category contains HPV16 2. 1. The vaccine of claim 20 which consists of HPV18VLPs 2. 2. The vaccine of claim 21, which follows HPV6. VLPs and H PV11 VLPs 2 3. Vaccine of claim 22 which is further composed of HPV31 VLPs 2 4. Vaccine of claim 21 which is further composed of HPV31 VLP s 2 5. Vaccine of claim 23 Which consists of HPV45VLPs 2 6. Vaccine of claim 24, which follows HPV45 VLPs 2. 7. Vaccine of claim 26, which follows HPV58 VLPs 2. 8. Vaccine of claim 25, in addition to HPV58 VLPs.